US 12,220,604 B2
Treatment of metastatic brain tumor by administration of an antibody-drug conjugate
Kiyoshi Sugihara, Tokyo (JP); and Chiaki Ishii, Tokyo (JP)
Assigned to DAIICHI SANKYO COMPANY, LIMITED, Tokyo (JP)
Appl. No. 17/264,250
Filed by DAIICHI SANKYO COMPANY, LIMITED, Tokyo (JP)
PCT Filed Jul. 30, 2019, PCT No. PCT/JP2019/029765
§ 371(c)(1), (2) Date Jan. 28, 2021,
PCT Pub. No. WO2020/027100, PCT Pub. Date Feb. 6, 2020.
Claims priority of application No. 2018-143372 (JP), filed on Jul. 31, 2018.
Prior Publication US 2021/0290777 A1, Sep. 23, 2021
Int. Cl. A61K 47/68 (2017.01); A61K 31/4745 (2006.01); A61K 47/54 (2017.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01)
CPC A61K 47/6843 (2017.08) [A61K 31/4745 (2013.01); A61K 47/545 (2017.08); A61K 47/68037 (2023.08); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); A61K 47/6855 (2017.08); A61K 47/6889 (2017.08); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07K 16/18 (2013.01); C07K 16/28 (2013.01); C07K 16/2827 (2013.01); C07K 16/30 (2013.01); C07K 16/32 (2013.01)] 57 Claims
 
1. A method of treating a metastatic brain tumor comprising, administering to a subject with a metastatic brain tumor an antibody-drug conjugate comprising a drug-linker conjugated to an antibody via a thioether bond, wherein the drug-linker comprises the following formula:

OG Complex Work Unit Chemistry
wherein A represents a connecting position to an antibody.